About CLINUVEL

About CLINUVEL

Experts in light and skinClinuvel's logo

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million.

CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been granted marketing authorisation by the European Commission for adults with EPP. Based in Melbourne, Australia, CLINUVEL has operations in Europe, the US and Singapore.

 

Latest Company Announcements

07 November 2017

Response to ASX Price Query

Response to ASX Price Query

Read More
30 October 2017

Appendix 4C

Appendix 4C

Read More
26 October 2017

Appendix 4G

Appendix 4G

Read More
16 October 2017

CLINUVEL Newsletter - October 2017

I am addressing you during quite a turbulent period, when our teams are preparing various dossiers to meet regulatory obligations in Europe and the US

Read More
10 October 2017

CLINUVEL CONFIRMS AGM DATE

CLINUVEL PHARMACEUTICALS LTD today announced it will hold its 2017 Annual General Meeting of shareholders on Tuesday 28 November 2017

Read More

Quick Links